Molecular Partners AG (MOLN)
|Net Income (ttm)||-71.32M|
|Trading Day||July 30|
|Day's Range||19.84 - 20.40|
|52-Week Range||18.00 - 21.33|
Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of $50, implying an upside potential of more than 150%. The company and its partner Novart...
Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrat...
ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR
Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States
Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial pu...
Molecular Partners AG has filed to go public with an IPO on the NASDAQ.
While the focus in Switzerland, and elsewhere, has been primarily on vaccines in the past few months, a new medication may also offer hope in the fight against Covid-19. This is what we know about this ...
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients.
Molecular Partners is a clinical stage biopharmaceutical company applying our pioneering DARPin® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology. Our DARPin platform, which is designed using ankyrin repeat proteins, allows us to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially offering patients products with higher efficacy and fewer adverse events. We believe that DARPin therapeutics represent a novel class... [Read more...]
|IPO Date |
Jun 16, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, MOLN's revenue was 9.34 million, a decrease of -54.16% compared to the previous year's 20.38 million. Losses were -62.76 million, 73.0% more than in 2019.